Published on

IMS Health Holdings Inc. and Quintiles Transnational Holdings are merging in an all-stock deal aimed at creating “a leading portfolio of anonymous patient records, technology-enabled data collection, and observational research experts to address critical healthcare issues of cost, value, and patient outcomes.” The new company, to be called Quintiles IMS Holdings, says its combined strength will be to support drug development from inception through demonstrating the value of new medicines. The 2015 combined revenue of the two companies was $7.2 billion. They estimate cost savings will reach about $100 million by the third year after closing, which is expected to take place in the latter half of 2016.

IMS Health–Quintiles Merger Weds Research and Information Technologies